Subclinical thyroid dysfunction

Archives of Internal Medicine

Volumn 157, Issue 10, 1997, Pages 1065-1068

  Woeber, Kenneth A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; LEVOTHYROXINE SODIUM; THYROTROPIN; THYROXINE;

DEPRESSION; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTHYROIDISM; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; THYROID DISEASE; THYROID FUNCTION TEST;

EID: 0030980341     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.10.1065     Document Type: Review

References (38)

1. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70:453-460.
2. Cavalieri RR. The effects of nonthyroid disease and drugs on thyroid function tests. Med Clin North Am. 1991;75:27-39.
3. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham Survey. Clin Endocrinol. 1977;7:481-493.
4. Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years: a study in an urban US community. Arch Intern Med. 1990; 150:785-787.
5. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid: thyroid deficiency in the Framingham Study. Arch Intern Med. 1985; 145:1386-1388.
6. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol. 1991;34:77-83.
7. Rosenthal MJ, Hunt WC, Garry PJ, Goodwin JS. Thyroid failure in the elderly: microsomal antibodies as discriminant for therapy. JAMA. 1987; 258:209-213.
8. Geul KW, van Sluisfeld ILL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clin Endocrinol. 1993;39:275-280.
9. Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43:55-68.
10. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Circulating lipids and minor abnormalities of thyroid function. Clin Endocrinol. 1992;37:411-414.
11. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotopin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92:631-642.
12. Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol. 1995;43:445-449.
13. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism: effect of levothyroxine therapy. Arch Intern Med. 1990; 150:2097-2100.
14. Caron Ph, Calazel C, Parra HJ, Hoff, M, Louvet JP. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol. 1990;33:519-523.
15. Elder J, McLelland A, O'Reilly D, Packard CJ, Series JJ, Shepherd J. The relationship between serum cholesterol and serum thyrotropin, thyroxine and triiodthyronine concentrations in suspected hypothyroidism. Ann Clin Biochem. 1990; 27:110-113.
16. Bogner U, Arntz H-R, Peters H, Schleusener H. Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified. Acta Endocrinol. 1993;128:202-206.
17. Franklyn JA, Daykin J, Betteridge J, et al. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol. 1993;38:453-459.
18. Miura S, Iitaka M, Yoshimura H, et al. Disturbed lipid metabolism in patients with subclinical hypothyroidism: effect of L-thyroxine therapy. Intern Med. 1994;33:413-417.
19. Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WW. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med. 1995;155:1490-1495.
20. Haggerty JJ Jr, Prange AR Jr. Borderline hypothyroidism and depression. Annu Rev Med. 1995; 46:37-46.
21. Custro N, Scafidi V, LoBaido R, et al. Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression. J Endocrinol Invest. 1994;17:641-646.
22. Joffe RT, Levitt AJ. Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology. 1992;17:215-221.
23. Jackson IMD. Does thyroid hormone have a role as adjunctive therapy in depression? Thyroid. 1996;6:63-67.
24. Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab. 1994;78:1368-1371.
25. 3) toxicosis. Am J Med. 1994;96:229-234.
26. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LE. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest. 1976;58: 529-534.
27. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment. Eur J Endocrinol. 1994; 130:350-356.
28. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women: effect of estrogen. JAMA. 1994; 271:1245-1249.
29. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M. Bone mineral density in thyroxine-treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol. 1994;41:425-432.
30. Müller CG, Bayley TA, Harrison JE, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid. 1995;5:81-87.
31. Garton M, Reid I, Loveridge N, et al. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol. 1994;41:747-755.
32. Franklyn JA, Betteridge J, Holder R, Sheppard MC. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated post-menopausal women with a past history of thyrotoxicosis. Thyroid. 1995;5:359-363.
33. Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med. 1993;95:385-388.
34. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med. 1992;327:94-98.
35. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252.
36. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993; 77:334-338.
37. Biondi B, Fazio S, Carella C, et al. Control of adrenergic overactivity by p-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1994;78: 1028-1033.
38. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β-blockade. J Clin Endocrinol Metab. 1995;80:2222-2226.